Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025

Core Insights - Cidara Therapeutics presented late-breaking Phase 2b clinical data on its influenza preventative candidate, CD388, at ID Week 2025, indicating its potential as a once-per-season preventative option against influenza A and B [1][2] Company Overview - Cidara Therapeutics is a biotechnology company utilizing its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) therapeutics, with CD388 being its lead candidate aimed at universal prevention of seasonal and pandemic influenza [3] - CD388 has received Fast Track Designation from the FDA and has progressed through clinical trials, with positive results from the Phase 2b NAVIGATE trial announced in June 2025 and the initiation of the Phase 3 ANCHOR trial in September 2025 [3] Clinical Data Summary - The Phase 2b NAVIGATE study demonstrated that CD388 provided significant prevention efficacy against influenza A and B in healthy, unvaccinated adults, with efficacy rates of 57.7% for 150 mg, 61.3% for 300 mg, and 76.1% for 450 mg doses [2] - CD388 was well tolerated with no apparent safety issues reported, suggesting its potential for season-long prevention of influenza illness in individuals not adequately protected by existing vaccines [2]